The possible benefits of apoA-I and apoA-II on survival and cardiovascular risk might thus be influenced by specific conditions such as inflammation, oxidative stress and malnutrition in patients with advanced chronic kidney disease (CKD) who undergo HD. This evidence concerns the gene APOA2 and chronic kidney disease.